Mercer Global Advisors Inc Cardiff Oncology, Inc. Transaction History

Mercer Global Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$2.11 - $7.25 $85,455 - $293,625	-40,500 Reduced 21.5%	147,857 $367,000
Q4 2021 Feb 04, 2022	BUY	$5.18 - $7.24 $77,700 - $108,600	15,000 Added 8.65%	188,357 $1.13 Million
Q3 2021 Nov 10, 2021	BUY	$5.01 - $7.58 $27,555 - $41,690	5,500 Added 3.28%	173,357 $1.16 Million
Q2 2021 Aug 10, 2021	BUY	$6.65 - $10.04 $66,500 - $100,399	10,000 Added 6.33%	167,857 $1.12 Million
Q1 2021 May 11, 2021	BUY	$9.1 - $19.57 $200,263 - $430,676	22,007 Added 16.2%	157,857 $1.46 Million
Q3 2020 Dec 10, 2020	BUY	$4.25 - $14.19 $850 - $2,838	200 Added 0.15%	135,850 $1.93 Million
Q2 2020 Aug 10, 2020	BUY	$0.78 - $5.1 $105,807 - $691,815	135,650 New	135,650 $680,000

125

25.3M

866K

203K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $160M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.